Pharmaceuticals, Biotechnology and Life Sciences
– Immune-Onc Expects Enrollment in its Phase 1 Trial to Begin in Q3 2020 – PALO ALTO, Calif.–(BUSINESS WIRE)–#AML–Immune-Onc Therapeutics,…
TOKYO & BASKING RIDGE, N.J. & MUNICH–(BUSINESS WIRE)–Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter,…
— Phase 1b Findings Presented in Oral Session at 2020 American Society of Clinical Oncology Annual Meeting Further Support CD47…
Collaboration initiates second Roche program utilizing Icagen’s ion channel drug discovery platform SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and…
DAEJEON, South Korea–(BUSINESS WIRE)–#ALTB4—Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of…
LOS ANGELES–(BUSINESS WIRE)–Lightship, a global direct-to-patient clinical trial company, announced today the results of a nationwide market research survey, designed…
Sernova to utilize AgeX’s UniverCyteTM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell PouchTM Platform ALAMEDA,…
BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer with a 41% reduction…
TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into…